Mon, Dec 29, 2014, 2:01 AM EST - U.S. Markets open in 7 hrs 29 mins


% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

  • gdenke gdenke Sep 10, 2013 7:18 AM Flag

    Neurocrine Biosciences (NBIX) 'Buy' Rating Intact at Jefferies Despite Setback


    Jefferies Thomas Wei defended Neurocrine Biosciences (NASDAQ: NBIX) after the company's VMAT2 inhibitor NBI-98854 failed to show a significant improvement at 50 mg over placebo in its primary endpoint of AIMS assessment at week 6 in its Phase 2b Kinect Trial in tardive dyskinesia, a form of movement disorder.

    "The data suggest that higher doses of '854 of 100mg or higher could safely improve efficacy, although the Kinect failure raises the risk profile around the drug. ‘854 remains upside to our valuation," Wei said.

    The firm maintained a Buy rating and price target of $16.00.

    For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

    Shares of Neurocrine Bio. closed at $16.70 yesterday, with a 52 week range of $6.72-$16.74.

    This topic is deleted.
22.77+1.44(+6.75%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.